BACKGROUND: Genetic variation in two members of the Toll-like receptor family, TLR4 and the gene cluster TLR6-1-10, has been implicated in prostate cancer in several studies but the associated alleles have not been consistent across reports. METHODS: We did a pooled analysis combining genotype data from three case-control studies, Cancer of the Prostate in Sweden, the Health Professionals Follow-up Study, and the Prostate, Lung, Colon and Ovarian Cancer Screening Trial, with data from 3,101 prostate cancer cases and 2,523 controls. We did imputation to obtain dense coverage of the genes and comparable genotype data for all cohorts. In total, 58 single nucleotide polymorphisms in TLR4 and 96 single nucleotide polymorphisms in TLR6-1-10 were genotyped or imputed and analyzed in the entire data set. We did a cohort-specific analysis as well as meta-analysis and pooled analysis. We also evaluated whether the analyses differed by age or disease severity. RESULTS: We observed no overall association between genetic variation at the TLR4 and TLR6-1-10 loci and risk of prostate cancer. CONCLUSIONS: Common germ line genetic variation in TLR4 and TLR6-1-10 did not seem to have a strong association with risk of prostate cancer. IMPACT: This study suggests that earlier associations between prostate cancer risk and TLR4 and TLR6-1-10 sequence variants were chance findings. To definitely assess the causal relationship between TLR sequence variants and prostate cancer risk, very large sample sizes are needed.
BACKGROUND: Genetic variation in two members of the Toll-like receptor family, TLR4 and the gene cluster TLR6-1-10, has been implicated in prostate cancer in several studies but the associated alleles have not been consistent across reports. METHODS: We did a pooled analysis combining genotype data from three case-control studies, Cancer of the Prostate in Sweden, the Health Professionals Follow-up Study, and the Prostate, Lung, Colon and Ovarian Cancer Screening Trial, with data from 3,101 prostate cancer cases and 2,523 controls. We did imputation to obtain dense coverage of the genes and comparable genotype data for all cohorts. In total, 58 single nucleotide polymorphisms in TLR4 and 96 single nucleotide polymorphisms in TLR6-1-10 were genotyped or imputed and analyzed in the entire data set. We did a cohort-specific analysis as well as meta-analysis and pooled analysis. We also evaluated whether the analyses differed by age or disease severity. RESULTS: We observed no overall association between genetic variation at the TLR4 and TLR6-1-10 loci and risk of prostate cancer. CONCLUSIONS: Common germ line genetic variation in TLR4 and TLR6-1-10 did not seem to have a strong association with risk of prostate cancer. IMPACT: This study suggests that earlier associations between prostate cancer risk and TLR4 and TLR6-1-10 sequence variants were chance findings. To definitely assess the causal relationship between TLR sequence variants and prostate cancer risk, very large sample sizes are needed.
Authors: Jielin Sun; Fredrik Wiklund; S Lilly Zheng; Baoli Chang; Katarina Bälter; Liwu Li; Jan-Erik Johansson; Ge Li; Hans-Olov Adami; Wennuan Liu; Amy Tolin; Aubrey R Turner; Deborah A Meyers; William B Isaacs; Jianfeng Xu; Henrik Grönberg Journal: J Natl Cancer Inst Date: 2005-04-06 Impact factor: 13.506
Authors: Meredith Yeager; Nick Orr; Richard B Hayes; Kevin B Jacobs; Peter Kraft; Sholom Wacholder; Mark J Minichiello; Paul Fearnhead; Kai Yu; Nilanjan Chatterjee; Zhaoming Wang; Robert Welch; Brian J Staats; Eugenia E Calle; Heather Spencer Feigelson; Michael J Thun; Carmen Rodriguez; Demetrius Albanes; Jarmo Virtamo; Stephanie Weinstein; Fredrick R Schumacher; Edward Giovannucci; Walter C Willett; Geraldine Cancel-Tassin; Olivier Cussenot; Antoine Valeri; Gerald L Andriole; Edward P Gelmann; Margaret Tucker; Daniela S Gerhard; Joseph F Fraumeni; Robert Hoover; David J Hunter; Stephen J Chanock; Gilles Thomas Journal: Nat Genet Date: 2007-04-01 Impact factor: 38.330
Authors: Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe; Jianfeng Xu; Henrik Grönberg; Charles G Drake; Yasutomo Nakai; William B Isaacs; William G Nelson Journal: Nat Rev Cancer Date: 2007-04 Impact factor: 60.716
Authors: Yen-Ching Chen; Edward Giovannucci; Ross Lazarus; Peter Kraft; Shamika Ketkar; David J Hunter Journal: Cancer Res Date: 2005-12-15 Impact factor: 12.701
Authors: S Lilly Zheng; Katarina Augustsson-Bälter; Baoli Chang; Maria Hedelin; Liwu Li; Hans-Olov Adami; Jeanette Bensen; Ge Li; Jan-Erik Johnasson; Aubrey R Turner; Tamara S Adams; Deborah A Meyers; William B Isaacs; Jianfeng Xu; Henrik Grönberg Journal: Cancer Res Date: 2004-04-15 Impact factor: 12.701
Authors: Victoria L Stevens; Ann W Hsing; Jeffrey T Talbot; Siqun Lilly Zheng; Jielin Sun; Jinbo Chen; Michael J Thun; Jianfeng Xu; Eugenia E Calle; Carmen Rodriguez Journal: Int J Cancer Date: 2008-12-01 Impact factor: 7.396
Authors: Yen-Ching Chen; Edward Giovannucci; Peter Kraft; Ross Lazarus; David J Hunter Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-10 Impact factor: 4.254
Authors: Irene M Shui; Jennifer R Stark; Kathryn L Penney; Fredrick R Schumacher; Mara M Epstein; Michael J Pitt; Meir J Stampfer; Rulla M Tamimi; Sara Lindstrom; Howard D Sesso; Katja Fall; Jing Ma; Peter Kraft; Edward Giovannucci; Lorelei A Mucci Journal: Prostate Date: 2011-05-11 Impact factor: 4.104
Authors: Jonah R Riddell; Wiam Bshara; Michael T Moser; Joseph A Spernyak; Barbara A Foster; Sandra O Gollnick Journal: Cancer Res Date: 2011-02-22 Impact factor: 12.701
Authors: Michael C Wu; Arnab Maity; Seunggeun Lee; Elizabeth M Simmons; Quaker E Harmon; Xinyi Lin; Stephanie M Engel; Jeffrey J Molldrem; Paul M Armistead Journal: Genet Epidemiol Date: 2013-03-07 Impact factor: 2.135
Authors: Yen Ching Chen; Yi Ling Huang; Elizabeth A Platz; John F Alderete; Lu Zheng; Jennifer R Rider; Peter Kraft; Edward Giovannucci; Siobhan Sutcliffe Journal: Cancer Causes Control Date: 2012-11-21 Impact factor: 2.506